A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma.
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jeffrey A. Zonder, Noopur S. Raje, Emma Catherine Scott, Craig C. Hofmeister, Nikoletta Lendvai, Larry Don Anderson, Parameswaran Hari, Gregory Joshua Orloff, Jesus G. Berdeja, Seema Singhal, Michael Craig, Jason Neil Valent, Mieke Ptaszynski, Jennifer Schreiber, Roger Aitchison, Saad Zafar Usmani
Institutions: The Barbara Ann Karmanos Cancer Institute, Massachusetts General Hospital, Oregon Health & Science University, The Ohio State University, Memorial Sloan Kettering Cancer Center, The University of Texas Southwestern Medical Center, Medical College of Wisconsin, Nova Scotia Cancer Centre, Sarah Cannon, Northwestern University, West Virginia University, Cleveland Clinic, Array BioPharma (United States), Carolinas Healthcare System, Levine Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2390773907